Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 20–21
HOS-134517 · Präparat HOS-097580
20
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Geometric mean change Recommendations concerning co-
therapeutic areas (%) administration
Buprenorphine/naloxone buprenorphine AUC ↓ 11% The clinical relevance of the
8/2 mg–16/4 mg once daily buprenorphine Cmin ↔ increase in norbuprenorphine
buprenorphine Cmax ↓ 8% pharmacokinetic parameters has not
norbuprenorphine AUC ↑ 46% been established. Dose adjustment
for buprenorphine may not be
norbuprenorphine Cmin ↑ 71% necessary when co- administered
norbuprenorphine Cmax ↑ 36% with darunavir/ritonavir but a
naloxone AUC ↔ careful clinical monitoring for signs
naloxone Cmin ND of opiate toxicity is recommended.
naloxone Cmax ↔
Fentanyl Based on theoretical considerations Clinical monitoring is
Oxycodone boosted darunavir may increase plasma recommended when co-
Tramadol concentrations of these analgesics. administering boosted darunavir
(CYP2D6 and/or CYP3A inhibition) with these analgesics.
OESTROGEN-BASED CONTRACEPTIVES
Drospirenone Not studied with darunavir/ritonavir. When darunavir is coadministered
Ethinylestradiol with a drospirenone-containing
(3 mg/0.02 mg once daily) product, clinical monitoring is
recommended due to the potential
Ethinylestradiol ethinylestradiol AUC ↓ 44% β for hyperkalaemia.
Norethindrone ethinylestradiol Cmin ↓ 62% β
35 μg/1 mg once daily ethinylestradiol Cmax ↓ 32% β Alternative or additional
norethindrone AUC ↓ 14% β contraceptive measures are
norethindrone Cmin ↓ 30% β recommended when oestrogen-
norethindrone Cmax ↔ β based contraceptives are co-
β administered with darunavir and
with darunavir/ritonavir
low dose ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): oxycodone (HOS-109487) buprenorphine (HOS-086193) drospirenone (HOS-116422) naloxone (HOS-109490) norethindrone (HOS-088136) fentanyl (HOS-086196) ritonavir (HOS-084521) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 828326375ee3543aa99e688f0802ddda7558a342c02a2b95eb3e81f3166f6273 · Zeichen 58739–61404 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 62–63
HOS-134632 · Präparat HOS-097580
62
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Recommendations concerning co-
therapeutic areas Geometric mean change (%) administration
Buprenorphine/naloxone buprenorphine AUC ↓ 11% The clinical relevance of the increase
8/2 mg–16/4 mg once daily buprenorphine Cmin ↔ in norbuprenorphine pharmacokinetic
buprenorphine Cmax ↓ 8% parameters has not been established.
norbuprenorphine AUC ↑ 46% Dose adjustment for buprenorphine
may not be necessary when co-
norbuprenorphine Cmin ↑ 71%
administered with boosted darunavir
norbuprenorphine Cmax ↑ 36% but a careful clinical monitoring for
naloxone AUC ↔ signs of opiate toxicity is
naloxone Cmin ND recommended.
naloxone Cmax ↔
Fentanyl Based on theoretical considerations Clinical monitoring is recommended
Oxycodone boosted darunavir may increase when co-administering boosted
Tramadol plasma concentrations of these darunavir with these analgesics.
analgesics.
(CYP2D6 and/or CYP3A
inhibition)
OESTROGEN-BASED CONTRACEPTIVES
Drospirenone drospirenone AUC ↑ 58%€ When darunavir is coadministered
Ethinylestradiol drospirenone Cmin ND€ with a drospirenone-containing
(3 mg/0.02 mg once daily) drospirenone Cmax ↑ 15%€ product, clinical monitoring is
ethinylestradiol AUC ↓ 30%€ recommended due to the potential for
ethinylestradiol Cmin ND € hyperkalaemia.
ethinylestradiol Cmax ↓ 14% €
€
with darunavir/cobicistat Alternative or additional
contraceptive measures are
recommended when oestrogen-based
Ethinylestradiol ethinylestradiol AUC ↓ 44%
contraceptives are co- administered
Norethindrone ethinylestradiol Cmin ↓ 62%
with boosted darunavir. Patients
35 μg/1 mg once daily ethinylestradiol Cmax ↓ 32%
using oestrogens as hormone
norethindrone AUC ↓ 14%
replacement therapy should be
norethindrone Cmin ↓ 30%
clinically monitored for signs of
norethindrone Cmax ↔
β oestrogen deficiency.
with darunavir/ritonavir
OPIOID ANTAGONIST
Naloxegol Not studied. Co-administration of boosted
darunavir and naloxegol is
contraindicated.
PHOSPHODIESTERASE, TYPE 5 (PDE-5) INHIBITORS
For the treatment of erectile In an interaction study #, a The combination of avanafil and
dysfunction comparable systemic exposure to boosted darunavir is contraindicated
Avanafil sildenafil was observed for a single (see section 4.3).
Sildenafil intake of 100 mg sildenafil alone Concomitant use of other PDE-5
Tadalafil and a single intake of 25 mg inhibitors for the treatment of erectile
Vardenafil sildenafil co-administered with dysfunction with boosted darunavir
darunavir and low dose ritonavir. should be done with caution. If
concomitant use of boosted darunavir
with sildenafil, vardenafil or tadalafil
is indicated, sildenafil at a single
dose not exceeding 25 mg in 48
hours, vardenafil at a single dose not
exceeding 2.5 mg in 72 hours or
tadalafil at a single dose not
exceeding 10 mg in 72 hours is
recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tadalafil (HOS-086316) oxycodone (HOS-109487) cobicistat (HOS-088111) avanafil (HOS-086161) buprenorphine (HOS-086193) drospirenone (HOS-116422) naloxegol (HOS-109428) naloxone (HOS-109490) norethindrone (HOS-088136) sildenafil (HOS-086162) fentanyl (HOS-086196) ritonavir (HOS-084521) vardenafil (HOS-086163) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage d56ddc78f27b4c72538384098965cc18c63cb876895fa8b1ad23ac8e5c655b68 · Zeichen 63992–69471 im Abschnitt
Wechselwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 15–16
HOS-138495 · Präparat HOS-098200
15
OTHER LIPID MODIFYING AGENTS
Lomitapide Based on theoretical Co-administration is
considerations, Symtuza is contraindicated (see section 4.3).
expected to increase the exposure
of lomitapide when co-
administered.
(CYP3A inhibition)
H2-RECEPTOR ANTAGONISTS
Cimetidine Based on theoretical Symtuza can be co-administered
Famotidine considerations, no mechanistic with H2-receptor antagonists
Nizatidine interaction is expected. without dose adjustments.
Ranitidine
IMMUNOSUPPRESSANTS
Ciclosporin Based on theoretical considerations Concentration monitoring of the
Sirolimus DRV/COBI is expected to increase immunosuppressive agent must
Tacrolimus these immunosuppressant plasma be done when co-administration
concentrations. with Symtuza occurs.
(CYP3A inhibition)
Co-administration of ciclosporin is
expected to increase plasma
concentrations of tenofovir
alafenamide.
(P-gp inhibition) Concomitant use of everolimus
Everolimus and Symtuza is not
recommended.
INHALED BETA AGONISTS
Salmeterol Based on theoretical considerations
Concomitant use of salmeterol
DRV/COBI is expected to increase
and Symtuza is not
salmeterol plasma concentrations.
recommended. The combination
(CYP3A inhibition) may result in increased risk of
cardiovascular adverse events
with salmeterol, including QT
prolongation, palpitations and
sinus tachycardia.
NARCOTIC ANALGESICS/TREATMENT OF OPIOID DEPENDENCE
Buprenorphine/naloxone Based on theoretical considerations Dose adjustment for
DRV/COBI may increase buprenorphine may not be
buprenorphine and/or necessary when co-administered
norbuprenorphine plasma with Symtuza, but a careful
concentrations. clinical monitoring for signs of
opiate toxicity is recommended.
Methadone Based on theoretical considerations No adjustment of methadone dose
DRV/COBI may increase is expected when initiating
methadone plasma concentrations. co-administration with Symtuza.
Clinical monitoring is
With ritonavir-boosted darunavir, a recommended, as maintenance
small decrease in methadone therapy may need to be adjusted
plasma concentrations was in some patients.
observed. Consult the Summary of
Product Characteristics for
darunavir for further details.
Fentanyl Based on theoretical considerations Clinical monitoring is
Oxycodone DRV/COBI may increase plasma recommended when
Tramadol concentrations of these analgesics. co-administering Symtuza with
(CYP2D6 and/or CYP3A these analgesics.
inhibition)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) nizatidine (HOS-138496) methadone (HOS-086198) cimetidine (HOS-085835) lomitapide (HOS-086160) oxycodone (HOS-109487) famotidine (HOS-112087) buprenorphine (HOS-086193) salmeterol (HOS-086285) tacrolimus (HOS-085202) ranitidine (HOS-085660) everolimus (HOS-086310) naloxone (HOS-109490) sirolimus (HOS-085172) fentanyl (HOS-086196) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage 65d1745e79031f8ffd732f400ccf71034e05cacd98fcfff4372c4246da9af398 · Zeichen 33001–37311 im Abschnitt
Wechselwirkungen · Abiraterone Mylan
Abiraterone Mylan 500 mg film-coated tablets Abiraterone Mylan 1000 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6–7
HOS-146765 · Präparat HOS-099564
Caution is advised when administering with medicinal products activated by or metabolised by
CYP2D6, particularly with medicinal products that have a narrow therapeutic index. Dose reduction of
medicinal products with a narrow therapeutic index that are metabolised by CYP2D6 should be
considered. Examples of medicinal products metabolised by CYP2D6 include metoprolol, propranolol,
desipramine, venlafaxine, haloperidol, risperidone, propafenone, flecainide, codeine, oxycodone and
6
tramadol (the latter three medicinal products requiring CYP2D6 to form their active analgesic
metabolites).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propafenone (HOS-084530) codeine (HOS-090544) desipramine (HOS-086249) flecainide (HOS-086203) oxycodone (HOS-109487) risperidone (HOS-086280) venlafaxine (HOS-086573) haloperidol (HOS-085602) propranolol (HOS-084529) metoprolol (HOS-090094) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T13:57:00Z · SHA-256 a224b8fadc2ad3e1b1af874d8687b8e3d6bb14c5f714b2308f5ba81c1b78da11 · Passage a9cc920d256817b14b1f63c2e0f3f180122c84999c9d524c0d853b81bd110d77 · Zeichen 1564–2206 im Abschnitt
Wechselwirkungen · Akeega
Akeega 50 mg/500 mg film-coated tablets Akeega 100 mg/500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-150309 · Präparat HOS-100288
Effects of niraparib or abiraterone acetate on other medicinal products
CYP2D6 substrates
Abiraterone is an inhibitor of CYP2D6. In a clinical study to determine the effects of abiraterone
acetate plus prednisone (AAP) on a single dose of the CYP2D6 substrate dextromethorphan, the
systemic exposure (AUC) of dextromethorphan was increased approximately 2.9-fold. The AUC24 for
dextrorphan, the active metabolite of dextromethorphan, increased approximately 33%. Dose
reduction of medicinal products with a narrow therapeutic index that are metabolised by CYP2D6
should be considered. Examples of medicinal products metabolised by CYP2D6 include metoprolol,
propranolol, desipramine, venlafaxine, haloperidol, risperidone, propafenone, flecainide, codeine,
oxycodone and tramadol.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): niraparib (HOS-136825) propafenone (HOS-084530) codeine (HOS-090544) acetate (HOS-088133) desipramine (HOS-086249) flecainide (HOS-086203) oxycodone (HOS-109487) risperidone (HOS-086280) venlafaxine (HOS-086573) haloperidol (HOS-085602) propranolol (HOS-084529) dextromethorphan (HOS-109265) prednisone (HOS-084526) metoprolol (HOS-090094) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-17T15:30:00Z · SHA-256 1bec7f3e5f18e4fe578c0f49b6a9128776963f703a1a9503180dea643f434459 · Passage 704800110d63379fb341b1ca9221e58b93483aec5c2142b646bcbfc2ed920ac5 · Zeichen 1171–1951 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.